Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

40.40 -0.21 (-0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,064,711
Open 40.42
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 40.61
Today's Range 40.10 - 40.53
52wk Range 34.10 - 45.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
From Genentech
Via Business Wire

Performance

YTD
+15.6%
+15.6%
1 Month
-9.9%
-9.9%
3 Month
+4.0%
+4.0%
6 Month
-1.7%
-1.7%
1 Year
+4.1%
+4.1%

More News

Read More
S&P 500's Resurgence: A Deep Dive into Market Dynamics and Future Trajectories
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Top 3 Health Care Stocks You'll Regret Missing In October
Via Benzinga
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
Via Benzinga
Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results
Via Investor's Business Daily
Topics Government
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche
Via Investor's Business Daily
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
From Genentech
Via Business Wire
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
From Genentech
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
Via Benzinga
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
From Genentech
Via Business Wire
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
Via Benzinga
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly
Via Stocktwits
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
From Genentech
Via Business Wire
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout
Via Investor's Business Daily
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
Via MarketMinute
FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
Via TokenRing AI
Topics Artificial Intelligence
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
Via Investor's Business Daily
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Via Benzinga
Topics Government World Trade

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 40.40
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 10/31/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.